Home Insights Stocks

Stocks

Published 6 November 2025

AMC

Amcor earnings for the quarter (19.2c, vs 18.c expected) coming in a touch higher than expected, even as volumes were a bit weaker (Q126 volumes pretty much the same as Q425, and hence down ~2% YoY).

Operational improvements (cost out) helping (NA beverage particularly so). But also good to see “at least” wording creeping in for the FY26 synergy guide.

In other words, the integration of Berry is going very well. On the call mgmt called out numerous examples of both revenue and cost synergy, which is encouraging.

At the group level, margins lifted a touch, and FY26 earnings and cashflow guides were unchanged. Guidance doesn’t require or expect a lift in market conditions, although it seems fair to say it probably doesn’t expect them to deteriorate either. On the call management did reference a scenario in which they could see volumes improving in the 2H, based on the revenue synergies (the pipeline of new business wins that they are getting out of the merger), which seemed positive, but the base case would seem to be “conditions remain flat” and they’ll still hit full year guidance.

Gearing is still high, at 3.6x ND/EBITDA, although a small asset sale (~$100m) and the expectations around cashflows are forecast to put gearing at 3-3.2x come the end of the financial year. If they can get progress on the North American beverage sale, that would obviously degear a bit quicker.

NHF

NIB (private health insurer) maintaining guidance, and calling out the improvement in NZ.

That policy holder growth of ~3%, it is quite remarkable how much quicker NIB has been growing, relative to peers…

…which they’ve been doing for some time.

The AGM call touches on AI, and how NHF will get benefits from integrating AI. We do think of insurance as an industry well suited for AI (fairly scalable, consistent processes that don’t require enormous amounts of novel judgement, that benefit from data analysis used to firm up pricing and risk).

We also think that the private health insurance companies are keen to do all that they can to keep people out of hospitals, as a cost efficiency program. And that can open up new revenue streams, as the private health insurance companies are, to various degrees, attempting to be involved in the medical market place in the context of advice. NHF has Honeysuckle and Midnight Health, businesses aimed at helping those with chronic conditions by putting together long term plans/treatment plans, or to get help via telehealth for those who need to speak with a medical practitioner in rural areas in the dead of night.

These are small, but will grow, in time, and have the highly synergistic effect of reducing cost in the primary health insurance arm.

BRG

Breville didn’t downgrade, which I suppose some in the market had (us included) worried about. The consumer in the US has weakened, and with the tariffs lurking about we thought the odds of a disappointment were reasonably high.

BRG point out the premium consumer is still doing well (although BRG aren’t exclusively high end, so the door to disappoint sort of seems still open).

In any case, further guidance will have to wait till Feb.

JHX

James Hardie out with a “please explain” letter from the ASX regarding the extraordinary move in the share price from ~$29 to $24. They’ve pointed to the MSCI Australia index deletion as a possible reason for the move, but that is borderline self evidently not going to move the market by a full quarter.

There was a peer in the US that does decking, and they reported weak quarterly sales. That’s new, bad news on the sector. Equally, the JHX AGM update was only a couple days ago, which came and went without an update (as in, material new news).

The October quarterly sales (preliminary) update was also pretty recent. That was the one where Hardies surprised to the upside, with numbers that were better than expected, after having really only just downgraded them a few weeks prior.

At the time, siding was holding up better than expected (down in the mid-high single digits) and decking (the AZEK part) had a seemingly good quarter with positive sales.

So the competitor news overnight, if it meant conditions had deteriorated such that JHX was required to revise (again!), then they would presumably have done so given a) today’s “please explain” notice from the ASX b) the AGM which just went c) the October sales update, where they actually gave a modest upgrade relative to market both in terms of how the quarter went and in terms of optimism expressed. So whilst it’s not particularly clear what’s going on, the opportunity to tell the market “something” came and went. Unless JHX wants an open and shut case of securities naughtiness (from not actually obeying continuous disclosure requirements) one concludes things are tracking to the prior expectation?

None of this is good news, and it is possible the above reads as very weak tea. Wild gyrations in the share price, the board spill, the extreme negative sentiment out there in the market, and all of that is before mentioning that US housing markets are indeed quite weak, given high interest rates and poor affordability.

However, we are also quite sure the James Hardie share price is not representing reality, at the moment. The extreme moves are, we think, sufficient evidence to suggest that trading is uninformed.

We have a small exposure, within direct equities, and we think there is a good business underneath all of this, a business that in both legacy JHX and legacy AZEK has been around for a long, long time.

NAB

The banks demonstrating once again why they are priced like growth stocks (say 20x and more). Clearly, that’s tongue in cheek; profits were flat, essentially no earnings growth whatsoever.

Still, volume growth picked up quite a bit in the second half, with business lending running at 1.3x system (5.8% growth).

Like most of the banks, the issue isn’t so much the top line growth, it’s expenses, which are eating up most of the increase. NABs 2H25 vs 1H25 expenses grew at 5%. So gross loans were something like +~6%, deposits closer to +7.4% (growing loan books, and funding them via attracting deposits is what a bank does) is going fine, but netting out the income and after that the expenses leaves little growth left.

Still, there was nothing particularly exciting happening at the segment level either, with all units pretty flat.

The NIM did rise from 1.7%, to 1.78%, mostly due to movements in the replicating portfolio, lending margins and funding cost movements (as a NIM contributor) were flat.

Asset quality seemed to improve a touch, in that whilst non performing loans (as a % of gross loans) rose, the watch loans number declined. Collective provisions declined a touch.

Bit of a mixed bag, really, but I think overall it’s fair to say the bad debt environment is still very, very benign for the majors. And since house prices are growing again, the risk of negative equity seems remote, at least as of right now.

The issue for NAB, like all the banks, is that it is a) geared b) expensive c) highly competitive out there d) strong expense growth environment. That’s a tough backdrop to keep outperforming against.

Important Information: This document has been prepared by Aequitas Investment Partners Pty Ltd ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of AIP FS Pty Ltd ABN 49 680 982 478 (Australian Financial Services Licensee no. 700016) and is for distribution within Australia to wholesale clients only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Aequitas is not authorised to provide tax (financial) advice and is not a registered tax agent. Investors should seek their own tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law. We recommend that you consult a registered tax agent or a tax specialist to confirm your taxation position.

Share this post

Do you want to stay ahead of the market?

Sign up to receive daily updates on investment topics and monthly updates on portfolios directly from the desks of our Joint Chief Financial Officers.
Stay ahead of the market and receive adviser insights straight to your inbox.